Drug Trial Radar · NCT03385655
Prostate Cancer Biomarker Enrichment and Treatment Selection
Last checked: Nov 20, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Actual
Start
Aug 1, 2018
Primary completion
Oct 7, 2024
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Canadian Cancer Clinical Trials Network; BC Cancer Foundation
- First posted
- Dec 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.
Conditions
- Prostate Cancer
Interventions
AdavosertibDrug
250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1
SavolitinibDrug
600mg once daily, orally.
DarolutamideDrug
600mg twice daily, orally.
CFI-400945Drug
Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.
IpatasertibDrug
400mg daily 3 weeks on, 1 week off
Durvalumab and TremelimumabDrug
Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
CarboplatinDrug
AUC 5 IV 60min Day 1 q 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical benefit rate defined as proportion of patients who had PSA decline ≥ 50%, complete or partial objective response, or Stable disease for ≥ 12 weeks.Time frame: 2 years
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Cross Cancer Institute
Edmonton, Alberta, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
The Jewish General Hospital
Montreal, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.